("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppression"[Mesh] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppressive Agents"[Mesh]
|
|
- Spencer Price
- 6 years ago
- Views:
Transcription
1 SEARCH STRATEGY PubMed: ("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppression"[Mesh] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppressive Agents"[Mesh] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Antilymphocyte Serum"[Mesh] ("regulatory t cells"[title/abstract]) AND "alemtuzumab"[title/abstract] ("T-Lymphocytes, Regulatory"[Mesh]) AND "basiliximab" [Supplementary Concept] ("T-Lymphocytes, Regulatory"[Mesh]) AND "daclizumab" [Supplementary Concept] ("regulatory t cells"[title/abstract]) AND "calcineurin inhibitors"[title/abstract] ("regulatory t cells"[title/abstract]) AND "cyclosporine"[title/abstract] ("regulatory t cells"[title/abstract]) AND "tacrolimus"[title/abstract] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Sirolimus"[Mesh] ("regulatory t cells"[title/abstract]) AND "rapamycin"[title/abstract] ("regulatory t cells"[title/abstract]) AND "everolimus"[title/abstract] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Graft Rejection"[Mesh] ("regulatory t cells"[title/abstract]) AND "acute rejection"[title/abstract] ("regulatory t cells"[title/abstract]) AND "graft function"[title/abstract] Ovid MEDLINE(R): (regulatory t cells and immunosuppression).ab. (regulatory t cells and thymoglobulin).ab.
2 (regulatory t cells and anti-cd25).ab. (regulatory t cells and calcineurin inhibitors).ab. (regulatory t cells and cyclosporine).ab. (regulatory t cells and tacrolimus).ab. (regulatory t cells and sirolimus).ab. (regulatory t cells and rapamycin).ab. (regulatory t cells and everolimus).ab. (regulatory t cells and acute rejection).ab. (regulatory t cells and graft function).ab. ClinicalKey: regulatory t cells and thymoglobulin regulatory t cells and anti-thymphocyte globulin regulatory t cells and alemtuzumab regulatory t cells and basiliximab regulatory t cells and daclizumab regulatory t cells and calcineurin inhibitors regulatory t cells and cyclosporine regulatory t cells and tacrolimus regulatory t cells and mammalian target of rapamycin inhibitors regulatory t cells and sirolimus regulatory t cells and rapamycin regulatory t cells and everolimus
3 regulatory t cells and acute rejection regulatory t cells and graft function Scopus: regulatory t cells and thymoglobulin regulatory t cells and anti-thymphocyte globulin regulatory t cells and alemtuzumab regulatory t cells and basiliximab regulatory t cells and daclizumab regulatory t cells and cyclosporine regulatory t cells and tacrolimus regulatory t cells and sirolimus regulatory t cells and rapamycin regulatory t cells and everolimus regulatory t cells and acute rejection regulatory t cells and graft function Cochrane Central Register of Controlled Trials (CENTRAL): (REGULATORY T CELLS AND IMMUNOSUPPRESSION):TA (REGULATORY T CELLS AND THYMOGLOBULIN):TA (REGULATORY T CELLS AND ANTI-THYMOCYTE GLOBULIN):TA (REGULATORY T CELLS AND ALEMTUZUMAB):TA
4 (REGULATORY T CELLS AND BASILIXIMAB):TA (REGULATORY T CELLS AND DACLIZUMAB):TA (REGULATORY T CELLS AND CYCLOSPORINE):TA (REGULATORY T CELLS AND TACROLIMUS):TA (REGULATORY T CELLS AND SIROLIMUS):TA (REGULATORY T CELLS AND RAPAMYCIN):TA (REGULATORY T CELLS AND EVEROLIMUS):TA (REGULATORY T CELLS AND ACUTE REJECTION):TA (REGULATORY T CELLS AND GRAFT FUNCTION):TA ClinicalTrials.gov: regulatory t cells AND immunosuppression regulatory t cells AND immunosuppressive agents regulatory t cells AND thymoglobulin regulatory t cells AND anti-thymphocyte globulin regulatory t cells AND alemtuzumab regulatory t cells AND basiliximab regulatory t cells AND daclizumab regulatory t cells AND cyclosporine regulatory t cells AND tacrolimus regulatory t cells AND sirolimus regulatory t cells AND rapamycin regulatory t cells AND everolimus
5 regulatory t cells AND acute rejection regulatory t cells AND graft function Meeting abstracts archives: Sociedad Española de Nefrología : manual searches. European Renal Association European Dialysis and Transplantation Association (ERA-EDTA) : manual searches. American Society of Nephrology Kidney Week : manual searches American Transplant Congress 2012, 2013, 2015 y 2016: manual searches. World Transplant Congress 2014: manual searches. TESEO: células t reguladoras linfocitos t reguladores Thèses-en-ligne: céllules t regulatrices
6 DART-Europe E-Theses portal: regulatory t cells Open Access Theses and Dissertations: regulatory t cells
Date: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationOBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
More informationLiver Transplant Immunosuppression
Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be
More informationThe addition of anti-cd25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients GUIDELINES SEARCH STRATEGY
nep_2.fm Page 5 Friday, January 26, 200 6:46 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology120-558 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 20012S1584MiscellaneousCalcineurin
More informationTRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard
TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationAmerican Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.
American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant
More informationHeart Transplant: State of the Art. Dr Nick Banner
Heart Transplant: State of the Art Dr Nick Banner Heart Transplantation What is achieved Current challenges Donor scarcity More complex recipients Long-term limitations Non-specific Pharmacological Immunosuppression
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482
Immunosuppressive e therapy for kidney transplant in children and young people Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482 NICE 2018. All rights reserved. Subject
More informationTrends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant and relationship to BK virus infection
2565 Nephrol Dial Transplant (2012) 27: 2565 2570 doi: 10.1093/ndt/gfr675 Advance Access publication 13 December 2011 Trends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant
More informationProteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation
Trends Fritz in Transplant. Diekmann: 2011;5:139-43 Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation
More informationBelatacept: An Update of Ongoing Clinical Trials
Belatacept: An Update of Ongoing Clinical Trials Michael D. Rizzari, MD University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin Abstract Belatacept is a fusion protein
More information9/30/ DISCLOSURES. + First: Why immunosuppress? Transplant Immunosuppression and Prophylaxis
Transplant Immunosuppression and Prophylaxis Sarah Fitz, APN, MSN, ACNP-BC Loyola University Medical Center DISCLOSURES I am not being paid by any entity to endorse a specific product. Any mention of brand
More informationMaintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis(review)
Cochrane Database of Systematic Reviews Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis(review) Rodríguez-Perálvarez M, Guerrero-Misas M, Thorburn D,
More informationFellows Conference 01/21/2016
Fellows Conference 01/21/2016 Outline Basics of transplantation Benefits of transplantation Immunosuppressive medications Anatomy of Renal Transplantation Recipient Selection General medical condition.
More informationAljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia
Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia Immunosuppression in kidney transplantation Aljoša Kandus Renal Transplant Center, Department
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationSignificance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis
Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Hatem Ali 1,2, Atif Mohiuddin 2,3, Ajay Sharma 2,3, Mohsen El Kosi 2,4 and Ahmed Halawa
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationImmunosuppression: evolution in practice and trends,
American Journal of Transplantation 25; 5 (Part 2): 874 886 Blackwell Munksgaard Blackwell Munksgaard 25 Immunosuppression: evolution in practice and trends, 1993 23 Ron Shapiro a,, James B. Young b, Edgar
More informationRe: Final Appraisal Determination - Immunosuppressive therapy for kidney transplant in adults (review of technology appraisal guidance 85)
January 19 th, 2016 Dr Margaret Helliwell Vice chair National Institute for Health and Care Excellence 10 Spring Gardens London SW1A 2BU Dear Margaret Re: Final Appraisal Determination - Immunosuppressive
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481
Immunosuppressive e therapy for kidney transplant in adults Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 NICE 2018. All rights reserved. Subject to Notice of rights
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationThe Pennsylvania State University. The Graduate School. College of Medicine THE INFLUENCE OF INDUCTION THERAPY AND DIABETES ON
The Pennsylvania State University The Graduate School College of Medicine THE INFLUENCE OF INDUCTION THERAPY AND DIABETES ON GRAFT FAILURE AFTER KIDNEY TRANSPLANT A Thesis in Public Health Sciences by
More informationImage: Bruce Wetzel - Harry Schaefer, Wikimedia Commons
Image: Bruce Wetzel - Harry Schaefer, Wikimedia Commons Martin lversen Section of Lung Transplantation Rigshospitalet Copenhagen Denmark martin.iversen@dadlnet.dk Immunosuppression for the non-transplant
More informationHIV and transplant: obstacles and opportunities
HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More information1980s-1990s1990s 9/24/2010. David Wojciechowski and. Mary Kennedy-Breiner. Laurie Carlson. Janine Sabatte- Caspillo
Factors Influencing Length of Stay: 1980s-1990s1990s Mail the Get Well Cards Home!! Effectively Managing Shorter Length of Stays David Wojciechowski and Higher rejection rates Longer duration of induction
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationRelationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications
Original Article Relationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications G. R. Pourmand 1, S. Dehghani 1*, A. Saraji 1, S. Khaki 1,2, S. H. Mortazavi
More informationBetter than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct
Better than Google- Click on Immunosuppression Renal Transplant David Landsberg Oct 3 2008 OUTLINE History of Immunosuppression Trends in Immunosupression FK vs CYA Steroid Minimization CNI Avoidance Sirolimus
More informationCURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961
CURRICULUM VITAE July 5, 2014 Name Chang-Kwon Oh Date of Birth August 15, 1961 Present Academic & Hospital Appointment Professor, Department of Surgery Ajou University, School of Medicine Chief, Department
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationRyszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation
Trends in Transplant. 2011;5:115-20 Ryszard Grenda: Steroid-Free Pediatric Transplantation Early Steroid Withdrawal in Pediatric Renal Transplantation Ryszard Grenda Department of Nephrology, Kidney Transplantation
More informationInduction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies?
American Journal of Transplantation 2017; 17: 22 27 Wiley Periodicals Inc. Minireview 2016 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of American Society
More informationIntroduction. Induction Therapy in Lung Transplantation. Abstract. Key words. José María Borro 1 and Amparo Solé 2
Trends in Transplantation Transplant. 2011;5:196-204 Induction Therapy in Lung Transplantation José María Borro 1 and Amparo Solé 2 1 Department of Thoracic Surgery and Lung Transplantation, Hospital Universitario
More informationInnovation In Transplantation:
Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016 Disclosures Belatacept preclinical and clinical trial were
More informationCase Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
Case Reports in Transplantation, Article ID 190516, 4 pages http://dx.doi.org/10.1155/2014/190516 Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationSolid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions
Solid Organ Transplantation 1 Chapter 55. Solid Organ Transplant, Self-Assessment Questions Questions 1 to 9 are related to the following case: A 38-year-old white man is scheduled to receive a living-unrelated
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/381922/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER The Paediatric Working Party
More informationReduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival
Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationPancreas and Pancreas-Kidney Transplantation By: Kay R. Brown, CLCP
Pancreas and Pancreas-Kidney Transplantation By: Kay R. Brown, CLCP Pancreas transplant recipients are usually under age 50. The majority of pancreas transplants are performed on diabetics, who are generally
More informationHealth technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:
An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status
More informationProgress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationPotential Catalysts in Therapeutics
LIVER TRANSPLANTATION 20:S22 S31, 2014 SUPPLEMENT Potential Catalysts in Therapeutics Bruce A. Luxon Division of Gastroenterology-Hepatology, University of Iowa, Iowa City, IA Received July 23, 2014; accepted
More informationDRUG LEVEL MONITORING AND ADJUSTMENT Silvio Sandrini, Brescia, Italy Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain
DRUG LEVEL MONITORING AND ADJUSTMENT Silvio Sandrini, Brescia, Italy Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain Prof. Silvio Sandrini Division and Chair of Nephrology University
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP
More informationSteroid avoidance or withdrawal for kidney transplant recipients(review)
Cochrane Database of Systematic Reviews Steroid avoidance or withdrawal for kidney transplant recipients(review) HallerMC,RoyuelaA,NaglerEV,PascualJ,WebsterAC Haller MC, Royuela A, Nagler EV, Pascual J,
More informationThe privilege of induction avoidance and calcineurin inhibitors withdrawal in 2 haplotype HLA matched white kidney transplantation
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 The privilege of induction avoidance and calcineurin inhibitors withdrawal in 2 haplotype HLA matched white
More informationPractical considerations for the use of mtor inhibitors
Diekmann and Campistol Transplantation Research 2015, 4(Suppl 1):5 DOI 10.1186/s13737-015-0029-5 TRANSPLANTATION RESEARCH REVIEW Practical considerations for the use of mtor inhibitors Fritz Diekmann 1,2*
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationClinical decisions regarding immunosuppressive
PHARMACOLOGIC THERAPIES AND RATIONALES * Stuart D. Russell, MD ABSTRACT This article reviews evidence related to the use of induction therapy and longer-term combination immunosuppressive drug regimens
More informationImmunosuppression is now manageable in the
EVOLVING STRATEGIES FOR IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION: A REVIEW OF RECENT CLINICAL TRIALS* Stephen J. Tomlanovich, MD, Thomas C. Pearson, MD, DPhil, and Lorenzo Gallon, MD ABSTRACT When using
More informationChronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP
Chronic Kidney Disease & Transplantation Paediatrics : 2004 FRACP ANZDATA Registry Mode of First Treatment - Paediatric 14 12 10 8 6 4 2 0 0-4 y 5-9 y 10-14 y 15-19 y Hospital CAPD Hospital HD Hospital
More informationAcute rejection and late renal transplant failure: Risk factors and prognosis
Nephrol Dial Transplant (2004) 19 [Suppl 3]: iii38 iii42 DOI: 10.1093/ndt/gfh1013 Acute rejection and late renal transplant failure: Risk factors and prognosis Luis M. Pallardo Mateu 1, Asuncio n Sancho
More informationPleiotropic effects of mtor inhibitors : cardiovascular and cancer. Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble
Pleiotropic effects of mtor inhibitors : cardiovascular and cancer Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble Tehran August 2016 Why this topic? Since last year very little news in the immunosuppressive
More informationLow toxicity immunosuppressive protocols in renal transplantation. Ron Shapiro
LECTURE Low toxicity immunosuppressive protocols in renal transplantation Ron Shapiro Department of Surgery, Director, Renal Transplantation, Thomas E. Starzl, Transplantation Institute University of Pittsburgh,
More informationCAMPATH INDUCTION IN RENAL TRANSPLANTATION. by Kakit Edmond Chan. Thesis is submitted for the degree of MD [Res] of Imperial College London
CAMPATH INDUCTION IN RENAL TRANSPLANTATION by Kakit Edmond Chan Thesis is submitted for the degree of MD [Res] of Imperial College London Department of Medicine Imperial College London kkchan 1 Abstract
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationIt s just not that into you:
CSHP Clinical Symposium - It s just not that into you: The no-excuses truth to understanding rejection and transplant pharmacology Erica D. Greanya, PharmD Clinical Pharmacy Specialist Solid Organ Transplantation
More informationPediatric Kidney Transplantation
Pediatric Kidney Transplantation Vikas Dharnidharka, MD, MPH Associate Professor Division of Pediatric Nephrology Conflict of Interest Disclosure Vikas Dharnidharka, MD, MPH Employer: University of Florida
More informationManipulation of the Immune Response - Immunomodulation -
Manipulation of the Immune Response - Immunomodulation - Janeway s Immunobiology, 9 th ed., 2017. Ivana Novak Nakir Immune system Immune system make components, cells and organs that act together to defend
More informationEvaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients
Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients Catherine A. Pennington, 1 Sarah M. Tischer, 1 Eliza Lee, 2 Sun Lee, 2 James Sindelar,
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationImmunosuppressive therapy in liver transplantation
Journal of Hepatology 39 (2003) 664 678 Short Reviews on Liver Transplantation Associate Editor: Didier Samuel Immunosuppressive therapy in liver transplantation Filomena Conti 1, Emmanuel Morelon 2, Yvon
More informationTransplant Immunosuppression in 2017 Hepatobiliary Liver Transplant Symposium 2017
Transplant Immunosuppression in 2017 Hepatobiliary Liver Transplant Symposium 2017 Dr AJ Terblanche Paediatric Gastroenterology and Hepatology Unit, SBAH Paediatric Transplant Unit Wits Donald Gordon Medical
More informationReview of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation
Clin Pharmacokinet DOI 10.1007/s40262-017-0573-x REVIEW ARTICLE Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation Marieke van der Zwan 1
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationOverview of Immunosuppression in Renal Transplantation
Chapter 10 Overview of Immunosuppression in Renal Transplantation M. Ghanta, J. Dreier, R. Jacob and I. Lee Additional information is available at the end of the chapter http://dx.doi.org/10.5772/54865
More informationAlfonso H. Santos Jr., Michael J. Casey, and Karl L. Womer
Hindawi Journal of Transplantation Volume 217, Article ID 8132672, 1 pages https://doi.org/1.1155/217/8132672 Research Article Analysis of Risk Factors for Kidney Retransplant Outcomes Associated with
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationHeart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
More informationAlemtuzumab Induction in Renal Transplantation
original article Induction in Renal Transplantation Michael J. Hanaway, M.D., E. Steve Woodle, M.D., Shamkant Mulgaonkar, M.D., V. Ram Peddi, M.D., Dixon B. Kaufman, M.D., Ph.D., M. Roy First, M.D., Richard
More informationProton pump inhibitors do not increase the risk of acute rejection
ORIGINAL ARTICLE Proton pump inhibitors do not increase the risk of acute rejection G.A.J. van Boekel*, C.H.H. Kerkhofs, F. van de Logt, L.B. Hilbrands Department of Nephrology, Radboud University Medical
More informationHeart Transplantation in the United States,
American Journal of Transplantation 29; 9 (Part 2): 932 941 Wiley Periodicals Inc. No claim to original US government works Journal compilation C 29 The American Society of Transplantation and the American
More informationBy the way, I have a transplant..
By the way, I have a transplant.. Transplant patient for non-transplant surgery David Elliott No relevant disclosures Organ donation in Australia - 2017 Survival rates following organ donation have increased
More informationFor Immediate Release Contacts: Jenny Keeney Astellas US LLC (847)
For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) 317-5405 Lauren McDonnell GolinHarris (312) 729-4233 ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF (TACROLIMUS) IN CONJUNCTION WITH
More informationIncidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study
Nephrol Dial Transplant (2018) 33: 881 889 doi: 10.1093/ndt/gfx356 Advance Access publication 12 January 2018 Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation
More informationKDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
VOL 56, NO 2, AUGUST 2010 KDOQI COMMENTARY KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients Margaret Bia, MD, 1 Deborah B. Adey, MD, 2 Roy
More informationTrends in Transplant. 2013;7:3-10 Tainá Veras de Sandes-Freitas, et al.: Cytomegalovirus Infection and Everolimus
Trends in Transplant. 2013;7:3-10 Tainá Veras de Sandes-Freitas, et al.: Cytomegalovirus Infection and Everolimus Cytomegalovirus Infections in Everolimus-Based Treatment Tainá Veras de Sandes-Freitas,
More informationclevelandclinic.org/transplant
carolyn spiotta Pancreas/Kidney Transplant Recipient I feel so fortunate and thankful that I have received a second chance at life. Carolyn Spiotta, 44, Pittsburgh. Carolyn needed a new pancreas and kidney
More information2017 CST-Astellas Canadian Transplant Fellows Symposium
2017 CST-Astellas Canadian Transplant Fellows Symposium The Future of Transplantation Atul Humar, MD Atul Humar is a Professor in the Department of Medicine, University of Toronto. Dr. Humar received his
More informationTable S1. Clinical outcomes of the acceptable mismatch allocation model.
Table S1. Clinical outcomes of the acceptable mismatch allocation model. Recipient Age PRA Waiting Time (months) HLA mismatch (A/B/DR) HLAMatchmaker acceptable mismatch (years) (%) Actual Simulation Change
More informationEarly Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation
Trends in Transplantation Transplant. 2012;6:28-33 Early Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation Hallvard Holdaas Department
More informationSirolimus versus Calcineurin Inhibitor-based Immunosuppressive Therapy in Kidney Transplantation A 4-year Follow-up
Transplantation Sirolimus versus Calcineurin Inhibitor-based Immunosuppressive Therapy in Kidney Transplantation A 4-year Follow-up Mohsen Nafar, 1 Behrang Alipour, 2 Pedram Ahmadpoor, 1 Fatemeh Pour-Reza-Gholi,
More informationCombination of a Calcineurin Inhibitor and a Mammalian Target of Rapamycin Inhibitor: Not So Nephrotoxic As We Thought?
Trends in Transplant. 2011;5:49-56Helio Tedesco Silva Junior: Calcineurin and mtor inhibitor nephrotoxicity Combination of a Calcineurin Inhibitor and a Mammalian Target of Rapamycin Inhibitor: Not So
More informationRenal transplantation
NEPHROLOGY 2008; 13, S37 S43 doi:10.1111/j.1440-1797.2008.00996.x Renal transplantation Date written: November 2006 Final submission: July 2007 Author: Nigel Toussaint GUIDELINES No recommendations possible
More informationOHSU Digital Commons. Oregon Health & Science University. Tysen June Cullen. Scholar Archive. September 2012
Oregon Health & Science University OHSU Digital Commons Scholar Archive September 2012 Body mass index and the development of newonset diabetes mellitus or the worsening of preexisting diabetes mellitus
More information